Any current/future new fundraising through debt or equity?

No explicit mention of current or future fundraising through debt or equity in the transcript. The focus is on ongoing and planned capex for various projects (New facilities in Pitampura, Mumbai, Medical School, Guest House) to be funded over the next three to four years. Mention of capital inflow in the healthcare industry post-COVID and increased interest from the financial community in building hospitals, but no direct statement about Medanta raising funds. The company emphasizes sustainable and ethical growth with a long-term view, not radical or short-term capital raising. CFO Yogesh Kuma

Any current/future capex/capital investment/strategic investment?

INR 300 crores budgeted for medical school build-out (4-5 lakh sq ft) on 25 acres hospital campus; timeline 3-4 years. Ongoing Pitampura project (Delhi) with DLF partnership; delayed due to pollution clearances but fully on track. Indore project currently delayed and stuck in litigation; exploring alternative expansion options. South Delhi project delayed due to compliance and approval issues. Mumbai land acquisition completed; part of INR 370 crores capex in H1 FY25. Total capex guidance: ~INR 470 crores on existing units and INR 500 crores for Noida project over next 3-4 years. Major medical

Future growth expectations in sales/revenue/volumes?

The company expects continued robust volume-driven growth, supported by increased bed capacity and expanded clinical capabilities, especially in developing hospitals like Lucknow and Patna. Expansion includes capacity addition: 280 beds added in H1 FY25 (150 in Lucknow, 84 in Patna, 50 in Gurugram), with focus on ramping up occupancy. Introduction of advanced technology, e.g., Da Vinci Xi Surgical Robot, aims to improve patient outcomes and attract more patients. Matured hospitals show steady revenue growth: 13.5% YoY in Q2 FY25; developing hospitals growing at 4.2% YoY. International patient

Future growth expectations in earnings/operating earnings/profits/EPS?

Strong growth momentum was seen across network hospitals with highest ever quarterly revenue and EBITDA. Matured hospitals showed 13.5% YoY revenue growth; developing hospitals grew 4.2% YoY. EBITDA margins improved sequentially to around 25.3%-29.9% across different units. Expansion includes adding ~280 beds in H1 FY25 and investments in advanced technology like Da Vinci Xi Surgical Robot. Focus on ramping up occupancy in new beds and increasing clinical capabilities. Conservative tariff increases to maintain reasonable pricing, supporting steady margin improvement. Ongoing investments in new

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a current or expected order book or pending orders. Capex plans are detailed: INR 470 crores for existing units and INR 500 crores for Noida between Q4 FY25 and Q1 FY26. Projects in South Delhi and Indore are delayed with uncertain timelines. Other projects like Mumbai, Pitampura, Medical School, and Guest House are expected to be completed over the next 3-4 years. The DLF project in Delhi is fully on track but delayed due to pollution control clearances. Indore has legal issues with landlords; alternative expansion ideas are being explored. Overall,

IN US

Sale is live|00:00:00left today

Global Health LtdQ3 FY24Healthcare Services

Global Health Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,312P/E: 60.0Market Cap: ₹33.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects continued robust volume-driven growth, supported by increased bed capacity and expanded clinical capabilities, especially in developing hospitals like Lucknow and Patna.
→Expansion includes capacity addition: 280 beds added in H1 FY25 (150 in Lucknow, 84 in Patna, 50 in Gurugram), with focus on ramping up occupancy.
→Introduction of advanced technology, e.g., Da Vinci Xi Surgical Robot, aims to improve patient outcomes and attract more patients.
→Matured hospitals show steady revenue growth: 13.5% YoY in Q2 FY25; developing hospitals growing at 4.2% YoY.
→International patient revenue is currently around 6%, expected to grow as new NCR facilities come online, though subject to geopolitical risks.
→Focus remains on sustainable, ethical growth by strengthening existing services and expanding reach into new areas.
→Pipeline projects including new facilities in Pitampura, Mumbai, and Noida expected to contribute incrementally over 3-4 years.

Margin guidance

Category 3

→Strong growth momentum was seen across network hospitals with highest ever quarterly revenue and EBITDA.
→Matured hospitals showed 13.5% YoY revenue growth; developing hospitals grew 4.2% YoY.
→EBITDA margins improved sequentially to around 25.3%-29.9% across different units.
→Expansion includes adding ~280 beds in H1 FY25 and investments in advanced technology like Da Vinci Xi Surgical Robot.
→Focus on ramping up occupancy in new beds and increasing clinical capabilities.
→Conservative tariff increases to maintain reasonable pricing, supporting steady margin improvement.
→Ongoing investments in new facilities (e.g., Pitampura project) and strengthening existing hospital capacities expected to support medium-term growth over next 3-5 years.
→Emphasis on gradual, sustainable margin improvement through volume growth, operational efficiencies, and innovation.
→Net cash surplus of INR 7,186 million supports capex and expansion plans.
→Overall outlook: optimistic with steady EPS and profit growth expected as hospitals mature and occupancy increases.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of current or future fundraising through debt or equity in the transcript.
→The focus is on ongoing and planned capex for various projects (New facilities in Pitampura, Mumbai, Medical School, Guest House) to be funded over the next three to four years.
→Mention of capital inflow in the healthcare industry post-COVID and increased interest from the financial community in building hospitals, but no direct statement about Medanta raising funds.
→The company emphasizes sustainable and ethical growth with a long-term view, not radical or short-term capital raising.
→CFO Yogesh Kumar Gupta mentions capex plans but does not detail any planned fundraising.
→Overall, the discussion centers more around strategic investments and capex management rather than immediate fundraising plans.

Order book

→The transcript does not explicitly mention a current or expected order book or pending orders.
→Capex plans are detailed: INR 470 crores for existing units and INR 500 crores for Noida between Q4 FY25 and Q1 FY26.
→Projects in South Delhi and Indore are delayed with uncertain timelines.
→Other projects like Mumbai, Pitampura, Medical School, and Guest House are expected to be completed over the next 3-4 years.
→The DLF project in Delhi is fully on track but delayed due to pollution control clearances.
→Indore has legal issues with landlords; alternative expansion ideas are being explored.
→Overall, capex and project completion timelines provide a framework of upcoming commitments rather than a formal order book.

Capex plans

Yes

→INR 300 crores budgeted for medical school build-out (4-5 lakh sq ft) on 25 acres hospital campus; timeline 3-4 years.
→Ongoing Pitampura project (Delhi) with DLF partnership; delayed due to pollution clearances but fully on track.
→Indore project currently delayed and stuck in litigation; exploring alternative expansion options.
→South Delhi project delayed due to compliance and approval issues.
→Mumbai land acquisition completed; part of INR 370 crores capex in H1 FY25.
→Total capex guidance: ~INR 470 crores on existing units and INR 500 crores for Noida project over next 3-4 years.
→Major medical equipment purchases aligned with hospital development phases.
→Focus on expanding capacity (e.g., 118 beds added in Q2 FY25 at Lucknow and Patna).
→Commitment to sustainable, ethical growth and strengthening existing facilities alongside new expansions.

How does Global Health Ltd rank vs peers in Healthcare Services?

Pro feature

1Global Health Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Global Health Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio